Cargando…
Ovarian cancer immunotherapy: opportunities, progresses and challenges
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategi...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831814/ https://www.ncbi.nlm.nih.gov/pubmed/20146807 http://dx.doi.org/10.1186/1756-8722-3-7 |
_version_ | 1782178270256562176 |
---|---|
author | Liu, Bei Nash, John Runowicz, Carolyn Swede, Helen Stevens, Richard Li, Zihai |
author_facet | Liu, Bei Nash, John Runowicz, Carolyn Swede, Helen Stevens, Richard Li, Zihai |
author_sort | Liu, Bei |
collection | PubMed |
description | Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer. |
format | Text |
id | pubmed-2831814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28318142010-03-04 Ovarian cancer immunotherapy: opportunities, progresses and challenges Liu, Bei Nash, John Runowicz, Carolyn Swede, Helen Stevens, Richard Li, Zihai J Hematol Oncol Review Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer. BioMed Central 2010-02-10 /pmc/articles/PMC2831814/ /pubmed/20146807 http://dx.doi.org/10.1186/1756-8722-3-7 Text en Copyright ©2010 PLiu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Liu, Bei Nash, John Runowicz, Carolyn Swede, Helen Stevens, Richard Li, Zihai Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title_full | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title_fullStr | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title_full_unstemmed | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title_short | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
title_sort | ovarian cancer immunotherapy: opportunities, progresses and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831814/ https://www.ncbi.nlm.nih.gov/pubmed/20146807 http://dx.doi.org/10.1186/1756-8722-3-7 |
work_keys_str_mv | AT liubei ovariancancerimmunotherapyopportunitiesprogressesandchallenges AT nashjohn ovariancancerimmunotherapyopportunitiesprogressesandchallenges AT runowiczcarolyn ovariancancerimmunotherapyopportunitiesprogressesandchallenges AT swedehelen ovariancancerimmunotherapyopportunitiesprogressesandchallenges AT stevensrichard ovariancancerimmunotherapyopportunitiesprogressesandchallenges AT lizihai ovariancancerimmunotherapyopportunitiesprogressesandchallenges |